|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Entasis Therapeutics Holdings Inc. (ETTX) |
|
|
$2.19 0.00 (0.00%) as of 4:30 Fri 7/8
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
27,290,000 |
| Market
Cap: |
59.77(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.19 - $2.19 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
19,270,476 |
| Total Buy Value |
$0 |
$0 |
$0 |
$42,395,047 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Innoviva Strategic Opportunities Llc |
Former 10% Owner |
• • • |
2022-07-11 |
4 |
B |
$2.20 |
$16,717,391 |
I/I |
7,598,814 |
29,270,476 |
0.01 |
-100% |
|
| Triola Anna Diaz |
Chief Commercial Officer |
• – – |
2022-07-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(125,000) |
0 |
|
- |
|
| Keiley Elizabeth M |
General Counsel |
• – – |
2022-07-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(150,000) |
0 |
|
- |
|
| Hastings David C |
Director |
– • – |
2022-07-11 |
4 |
D |
$2.20 |
$60,500 |
D/D |
(27,500) |
0 |
|
- |
|
| Mayer Howard |
Director |
– • – |
2022-07-11 |
4 |
D |
$2.20 |
$60,500 |
D/D |
(27,500) |
0 |
|
- |
|
| Tommasi Ruben |
Chief Scientific Officer |
• – – |
2022-07-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(150,000) |
0 |
|
- |
|
| Perros Manoussos |
President and CEO |
• • – |
2022-07-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(478,500) |
0 |
|
- |
|
| Ronsheim Matthew |
Chief of Pharma Sciences & MFG |
• – – |
2022-07-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(150,000) |
0 |
|
- |
|
| Behanna Heather |
Director |
– • – |
2022-07-11 |
4 |
D |
$2.20 |
$60,500 |
D/D |
(27,500) |
0 |
|
- |
|
| Meek David D. |
Director |
– • – |
2022-07-11 |
4 |
D |
$2.20 |
$60,500 |
D/D |
(27,500) |
0 |
|
- |
|
| Mueller John Patrick |
Chief Development Officer |
• – – |
2022-07-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(150,000) |
0 |
|
- |
|
| Wagner Kristie Ann |
VP, Principal Fin & Acct Off |
• – – |
2022-07-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(80,500) |
0 |
|
- |
|
| Altarac David |
Chief Medical Officer |
• – – |
2022-07-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(150,000) |
0 |
|
- |
|
| Innoviva Strategic Opportunities Llc |
Former 10% Owner |
• • • |
2022-07-08 |
4 |
B |
$2.20 |
$25,677,656 |
I/I |
11,671,662 |
21,671,662 |
0.01 |
-100% |
|
| Keiley Elizabeth M |
General Counsel |
• – – |
2022-07-07 |
4 |
D |
$2.20 |
$38,658 |
D/D |
(17,572) |
0 |
|
- |
|
| Hastings David C |
Director |
– • – |
2022-07-07 |
4 |
D |
$2.20 |
$48,400 |
D/D |
(22,000) |
0 |
|
- |
|
| Mayer Howard |
Director |
– • – |
2022-07-07 |
4 |
D |
$2.20 |
$48,400 |
D/D |
(22,000) |
0 |
|
- |
|
| Tommasi Ruben |
Chief Scientific Officer |
• – – |
2022-07-07 |
4 |
D |
$2.20 |
$87,111 |
D/D |
(39,596) |
0 |
|
- |
|
| Perros Manoussos |
President and CEO |
• • – |
2022-07-07 |
4 |
D |
$2.20 |
$123,358 |
D/D |
(56,072) |
0 |
|
- |
|
| Ronsheim Matthew |
Chief of Pharma Sciences & MFG |
• – – |
2022-07-07 |
4 |
D |
$2.20 |
$38,658 |
D/D |
(17,572) |
0 |
|
- |
|
| Behanna Heather |
Director |
– • – |
2022-07-07 |
4 |
D |
$2.20 |
$48,400 |
D/D |
(22,000) |
0 |
|
- |
|
| Meek David D. |
Director |
– • – |
2022-07-07 |
4 |
D |
$2.20 |
$48,400 |
D/D |
(22,000) |
0 |
|
- |
|
| Mueller John Patrick |
Chief Development Officer |
• – – |
2022-07-07 |
4 |
D |
$2.20 |
$37,602 |
D/D |
(17,092) |
0 |
|
- |
|
| Altarac David |
Chief Medical Officer |
• – – |
2022-07-07 |
4 |
D |
$2.20 |
$38,658 |
D/D |
(17,572) |
0 |
|
- |
|
| Wagner Kristie Ann |
VP, Principal Fin & Acct OffOf |
• – – |
2022-02-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
70,500 |
|
22% |
|
98 Records found
|
|
Page 1 of 4 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
